162
Participants
Start Date
February 24, 2009
Primary Completion Date
March 6, 2017
Study Completion Date
March 6, 2017
Everolimus (EVR)
Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
cyclosporine A (CyA)
10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
tacrolimus (TAC)
0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
Enteric coated mycophenolate sodium (EC-MPS)
180 mg or 360 mg tablet dosed 1440-2280 mg per day
mycophenolate mofetil (MMF)
250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
Corticosteroids
according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Novartis Investigative Site, Berlin
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Bad Oeynhausen
Novartis Investigative Site, Münster
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, München
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Leipzig
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY